Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Research · May 19, 2021

Emricasan Use in HCV-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

Liver Transplantation

 

Additional Info

Liver Transplantation
Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis
Liver Transpl. 2021 Apr 01;27(4)568-579, EM Weinberg, MP Curry, CT Frenette, FG Regenstein, ER Schiff, ZD Goodman, JM Robinson, JL Chan, JC Imperial, KR Reddy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading